In short
Lomustine is being studied in clinical trials for several brain tumor settings, especially glioblastoma and medulloblastoma. These trials look at whether Lomustine helps improve survival, control disease, and can be used safely in different treatment plans. Some studies include adults, while others include children, teens, and young adults.
Key points
- Lomustine is being studied in several clinical trials for brain tumors, especially glioblastoma and medulloblastoma. The trials include adults, children, teens, and young adults, depending on the study. Most studies are in Phase 2 or Phase 3, with one Phase 4 trial also listed. The main goals are to see whether Lomustine-based treatment can improve overall survival, progression-free survival, or event-free survival. Some trials also measure safety, tolerability, quality of life, and brain-related function. In many studies, Lomustine is tested as part of a combination treatment rather than by itself.
Trial overview
Across the trial data, Lomustine is studied mainly in brain tumors, especially glioblastoma and medulloblastoma. It appears in both single-treatment comparisons and combination treatment plans, where researchers test whether adding it to other therapies improves results.
The studies are interventional trials, which means the research team assigns a treatment plan and then follows outcomes over time. The trial phases include Phase 2, Phase 3, and Phase 4, showing that Lomustine is being tested in both mid-stage and later-stage research.
Glioblastoma studies
Several trials focus on glioblastoma, a fast-growing brain tumor that often comes back after treatment. One Phase 3 study is testing TLX101-Tx plus standard care versus standard care alone in people with recurrent glioblastoma, and Lomustine is part of the treatment plan in that study.
Another Phase 2 trial compared Berubicin with Lomustine in adults with recurrent glioblastoma multiforme, with the main goal of checking overall survival. A separate Phase 3 trial is comparing Lomustine alone with Lomustine plus bevacizumab in recurrent glioblastoma, again with overall survival as the main endpoint.
There is also a Phase 2 trial in newly diagnosed glioblastoma testing standard treatment with ultrasound-induced blood brain barrier opening, and Lomustine is included among the listed drugs. Another withdrawn Phase 2 study planned to test L19TNF with Lomustine in glioblastoma at progression or recurrence, with safety and 12-month survival as key outcomes.
Medulloblastoma and other pediatric studies
Medulloblastoma trials also include Lomustine in several treatment programs. One large Phase 3 study is for clinically high-risk medulloblastoma in patients older than 3 years, and Lomustine is part of one of the maintenance chemotherapy options being studied.
A Phase 2 trial in newly diagnosed medulloblastoma for postpubertal and adult patients included Lomustine in the treatment plan, although the main comparison in the brief summary focused on another study drug and standard therapy. Another Phase 2 study looked at standard and high-dose chemotherapy with craniospinal irradiation in metastatic medulloblastoma and other embryonal tumors, and Lomustine was one of the drugs in the regimen.
The Phase 4 SIOP PNET 5 medulloblastoma trial includes Lomustine as part of risk-adapted treatment for children and adolescents with medulloblastoma. This study covers different risk groups, including standard-risk and high-risk biological profiles, and uses event-free survival as the main outcome.
Lomustine also appears in a Phase 3 study of newly diagnosed WHO grade 2 or 3 glioma with 1p/19q co-deletion, where the trial compares different treatment strategies and measures qualified overall survival, which combines survival with function, thinking, and quality of life.
Outcomes being measured
The main primary outcomes in these trials are mostly survival-based measures such as overall survival, progression-free survival, event-free survival, and qualified overall survival.
Overall survival means how long people live after entering the study. Progression-free survival means the time before the cancer gets worse or the person dies. Event-free survival means the time before a major event such as progression, relapse, or death.
Some studies also measure safety and tolerability, including adverse events, serious adverse events, laboratory tests, ECG, physical examination, and in some trials heart tests such as ECHO. One Phase 3 glioma study also measures whether survival happens without worsening in function, thinking, or quality of life, which is a more patient-centered outcome.
Who can participate
Eligibility depends on the specific trial and the tumor type. Some studies are for adults with recurrent glioblastoma, while others include children, adolescents, young people, or adults with medulloblastoma or other embryonal tumors.
Some trials are limited to newly diagnosed disease, while others focus on recurrence or progression after earlier treatment. In the medulloblastoma studies, risk group and tumor biology matter, such as high-risk disease, standard-risk disease, SHH subgroup, and 1p/19q co-deletion in glioma.
Trial phases and status
The Lomustine trials in the source data include Phase 2, Phase 3, and Phase 4 research.
Several trials are Authorised, meaning they are approved to begin or continue, while others are Completed or Withdrawn.
The trial designs are mostly randomized comparisons or treatment-program studies, which means researchers are trying to see whether one plan works better than another or whether a treatment combination is safe and useful.